reducing bladder cancer recurrence risk by 68% with cretostimogene versus surveillance.
https://finviz.com/stock?t=CGON&p=d
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.